These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36316100)

  • 21. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    van den Dries CJ; Pajouheshnia R; van den Ham HA; Souverein P; Moons KGM; Hoes AW; Geersing GJ; van Doorn S
    Br J Clin Pharmacol; 2023 Feb; 89(2):751-761. PubMed ID: 36102068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
    Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
    Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral anticoagulants and outcomes in adults ≥80 years with atrial fibrillation: A global federated health network analysis.
    Harrison SL; Buckley BJR; Ritchie LA; Proietti R; Underhill P; Lane DA; Lip GYH
    J Am Geriatr Soc; 2022 Aug; 70(8):2386-2392. PubMed ID: 35587227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
    Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
    Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis.
    Zhang XL; Zhang XW; Wang TY; Wang HW; Chen Z; Xu B; Xu W
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007971. PubMed ID: 34932377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis.
    Liu X; Huang M; Ye C; Xiao X; Yan C
    Clin Cardiol; 2021 Apr; 44(4):472-480. PubMed ID: 33682184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage.
    Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
    Stroke; 2020 Feb; 51(2):416-423. PubMed ID: 31813363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
    Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials.
    Harskamp RE; Lucassen WAM; Lopes RD; Himmelreich JCL; Parati G; Weert HCPMV
    Acta Cardiol; 2022 May; 77(3):191-195. PubMed ID: 33685380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review.
    Meinel TR; Frey S; Arnold M; Kendroud S; Fischer U; Kaesmacher J; Heldner MR; Jung S
    PLoS One; 2019; 14(3):e0213379. PubMed ID: 30925155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials.
    Sahay S; Nombela-Franco L; Rodes-Cabau J; Jimenez-Quevedo P; Salinas P; Biagioni C; Nuñez-Gil I; Gonzalo N; de Agustín JA; Del Trigo M; Perez de Isla L; Fernández-Ortiz A; Escaned J; Macaya C
    Heart; 2017 Jan; 103(2):139-147. PubMed ID: 27587437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.